Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7510-7519

  Gautam, Nagsen ^a   Puligujja, Pavan ^b   Balkundi, Shantanu ^b   Thakare, Rhishikesh ^a   Liu, Xin Ming ^b   Fox, Howard S ^b   McMillan, JoEllyn ^b   Gendelman, Howard E ^b   Alnouti, Yazen ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLATE RECEPTOR GAMMA; FOLIC ACID; POLOXAMER; RITONAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG CARRIER; NANOMATERIAL; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ELIMINATION RATE CONSTANT; LONG TERM EXPOSURE; MALE; MEAN RESIDENCE TIME; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; SINGLE DRUG DOSE; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG ADMINISTRATION; DRUG SCREENING; ELEMENTAL DIET; HALF LIFE TIME; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; RHESUS MONKEY; TISSUE DISTRIBUTION;

ANIMALS; ANTI-HIV AGENTS; ATAZANAVIR SULFATE; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; FOLIC ACID; FOOD, FORMULATED; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; OLIGOPEPTIDES; POLOXAMER; PYRIDINES; RITONAVIR; TISSUE DISTRIBUTION;

EID: 84912121180     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04108-14     Document Type: Article

References (30)

1. Ellis R, Langford D, Masliah E. 2007. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat. Rev. Neurosci. 8:33-44. http: //dx.doi.org/10.1038/nrn2040.
2. Work Group for HIV and Aging Consensus Project. 2012. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J. Am. Geriatr. Soc. 60:974-979. http://dx.doi.org/10.1111/j.1532-5415.2012.03948.x.
3. Anabwani G, Navario P. 2005. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 21:96-99. http://dx.doi.org/10.1016/j.nut .2004.09.013.
4. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. 2001. The global impact of HIV/AIDS. Nature 410:968-973. http://dx.doi.org/10 .1038/35073639.
5. Spreen WR, Margolis DA, Pottage JC, Jr. 2013. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV AIDS 8:565-571. http://dx.doi.org/10.1097/COH.0000000000000002.
6. Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE. 2011. Comparative manufacture and cellbased delivery of antiretroviral nanoformulations. Int. J. Nanomedicine 6:3393-3404. http://dx.doi.org/10.2147/IJN.S27830.
7. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. 2010. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol. 5:592-601. http://dx.doi.org/10.1007/s11481-010-9198-7.
8. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE. 2009. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond.) 4:903-917. http://dx.doi.org/10.2217/nnm.09.71.
9. Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y. 2013. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57:3110-3120. http://dx.doi.org/10.1128/AAC.00267-13.
10. Roy U, McMillan J, Alnouti Y, Gautum N, Smith N, Balkundi S, Dash P, Gorantla S, Martinez-Skinner A, Meza J, Kanmogne G, Swindells S, Cohen SM, Mosley RL, Poluektova L, Gendelman HE. 2012. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocytereconstituted mice. J. Infect. Dis. 206:1577-1588. http://dx.doi.org/10 .1093/infdis/jis395.
11. Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY. 2012. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26: 2135-2144. http://dx.doi.org/10.1097/QAD.0b013e328357f5ad.
12. Nowacek A, Gendelman HE. 2009. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond.) 4:557-574. http://dx.doi.org/10.2217 /nnm.09.38.
13. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. 2009. Macrophage delivery of nanoformulated antiretroviral drug to the brain in amurine model of neuroAIDS. J. Immunol. 183:661-669. http://dx.doi.org/10.4049/jimmunol.0900274.
14. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. 2006. Development of a macrophagebased nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835. http://dx.doi.org/10.1182/blood-2006-03-012534.
15. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, Ratnam M, Sanchez-Mateos P, Corbi AL. 2009. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69:9395-9403. http://dx.doi.org/10.1158/0008 -5472.CAN-09-2050.
16. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. 2009. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113:438-446. http://dx.doi.org/10.1182/blood-2008-04-150789.
17. Crowe S, Zhu T, Muller WA. 2003. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 74:635-641. http://dx.doi.org /10.1189/jlb.0503204.
18. Dandekar S. 2007. Pathogenesis of HIV in the gastrointestinal tract. Curr. HIV/AIDS Rep. 4:10-15. http://dx.doi.org/10.1007/s11904-007-0002-0.
19. Bergamaschi A, Pancino G. 2010. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7:31. http://dx.doi.org/10 .1186/1742-4690-7-31.
20. Martinez-Skinner AL, Veerubhotla RS, Liu H, Xiong H, Yu F, Mc-Millan JM, Gendelman HE. 2013. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity. J. Proteome Res. 12:2282-2294. http://dx.doi .org/10.1021/pr400185w.
21. Puligujja P, McMillan J, Kendrick L, Li T, Balkundi S, Smith N, Veerubhotla RS, Edagwa BJ, Kabanov AV, Bronich T, Gendelman HE, Liu XM. 2013. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 9(8):1263-1273. http://dx.doi.org/10.1016/j.nano.2013.05.003.
22. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. 1996. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate. J. Nucl. Med. 37:1003-1008.
23. Leamon CP, Reddy JA, Dorton R, Bloomfield A, Emsweller K, Parker N, Westrick E. 2008. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. J. Pharmacol. Exp. Ther. 327:918-925. http://dx.doi.org/10.1124/jpet.108.143206.
24. Kabanov AV, Gendelman HE. 2007. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 32:1054-1082. http://dx.doi.org/10.1016/j.progpolymsci.2007.05.014.
25. Gendelman HE, Kabanov A, Linder J. 2008. The promise and perils of CNS drug delivery: a video debate. J. Neuroimmune Pharmacol. 3:58. http://dx.doi.org/10.1007/s11481-008-9103-9.
26. Rathbun RC, Lockhart SM, Stephens JR. 2006. Current HIV treatment guidelines-an overview. Curr. Pharm. Des. 12:1045-1063. http://dx.doi .org/10.2174/138161206776055840.
27. Huang J, Gautam N, Bathena SP, Roy U, McMillan J, Gendelman HE, Alnouti Y. 2011. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879:2332-2338. http: //dx.doi.org/10.1016/j.jchromb.2011.06.032.
28. Zeldin RK, Petruschke RA. 2004. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53:4-9. http://dx.doi.org/10.1093/jac /dkh029.
29. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. 2013. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS 8:190-195. http://dx .doi.org/10.1097/COH.0b013e32835fc68a.
30. Tomaru A, Takeda-Morishita M, Banba H, Takayama K. 2013. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice. Drug Metab. Pharmacokinet. 28:144-152. http://dx.doi .org/10.2133/dmpk.DMPK-12-RG-057.